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Background/aim: The disease caused by SARS-CoV-2 was named as COVID-19. There is as yet insufficient information about the
effects of HSCT on the clinical course of COVID-19. In the present study, we aimed to investigate the clinical course of COVID-19 in
patients who had undergone HSCT.
Materials and methods: We analyzed baseline characteristics, clinical course and findings of COVID-19, hospitalization and death
rates, overall survival, and case fatality rates of HSCT recipients diagnosed with COVID-19 retrospectively.
Results: 57.6% of the patients underwent AHSCT, and 42.4% underwent allo-HSCT. 60.6%, 27.3%, and 12.1% of the patients had mild,
moderate, and severe COVID-19 or critical illness, respectively. Overall, 45.5% were hospitalized, 12.1% required intensive care, and
9.1% necessitated invasive mechanical ventilation. The total CFR was 9.1% in HSCT recipients, 22.2% in patients with active hematologic
malignancy, and 4.2% in patients without active hematologic malignancy.
Conclusion: It can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared
to ones that are not in remission. Further studies with larger group patients are needed in order to delineate the effects of COVID-19
on HSCT patients.
Key words: Hematopoietic stem cell transplantation, bone marrow transplant, COVID-19

1. Introduction
The disease caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first discovered in
Wuhan, China and named as coronavirus disease 2019
(COVID-19) then spread all over the world, and declared
as a pandemic by the World Health Organization [1].
Clinical course of the disease varies from asymptomatic
disease to significant morbidity and mortality due to
respiratory failure. Advanced age, male sex, hypertension,
diabetes mellitus, cardiovascular diseases, and cancer have
been shown as risk factors worsening outcomes. There are
studies that show higher mortality rates in hematologic
cancer patients [2,3]. The characteristics of the disease
course in immunosuppressive patients are not exactly
known yet [4]. Hematopoietic stem cell transplantation

(HSCT) recipients are considered to be at risk due to
severe immunosuppressive therapy and immune system
dysregulation after HSCT [5]. There is as yet insufficient
information about the effects of COVID-19 on the clinical
course of HSCT patients. In the present study, we aimed to
investigate the effects of COVID-19 in patients who had
undergone HSCT.
2. Materials and methods
According to the hospital medical records, 33 patients
followed in the stem cell transplantation unit of Hacettepe
University Hematology Department were diagnosed with
COVID-19 between 11th March and 30th November 2020.
The data of these patients was analyzed retrospectively.
COVID-19 was diagnosed with positive result of reverse-
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transcriptase polymerase chain reaction (RT-PCR) test
from upper respiratory samples or bronchoalveolar lavage
fluid. The disease with only mild symptoms (cough, fever,
anosmia, fatigue) was evaluated as mild disease. The
disease with clinical or radiological findings of pneumonia,
but not requiring supportive oxygen therapy was evaluated
as moderate disease. Patients with pneumonia and oxygen
saturation below 93% or respiratory rate above 30/min
were considered to have severe COVID-19. The condition
of the patients with respiratory failure, shock or multiorgan failure was evaluated as critical illness [6]. Some
high-risk patients with mild COVID-19 were hospitalized
for observation purposes only.
The approvals were obtained from the Turkish Ministry
of Health and the local ethics committee with decision
number 2020/20-54.
IBM SPSS Statistics for Windows v: 25.0 (IBM Corp.,
Armonk, NY, USA) was used for statistical analyses.
Categorical data was analyzed using Chi-square or
Fisher’s exact test. The distribution of continuous data
was examined. Mean ± standard deviation and median
(minimum-maximum) values were given for normally
distributed continuous and nonnormally distributed
variables, respectively. At the time of last follow-up,
patients who were alive were censored for overall survival
analysis. The Kaplan–Meier method was used for overall
survival analysis.
3. Results
Thirty-three patients were included in the study. Median
age was 57 (27–71) years. Nineteen (57.6%) of the
patients underwent autologous hematopoietic stem cell
transplantation (AHSCT), and 14 (42.4%) underwent
allogeneic hematopoietic stem cell transplantation (AlloHSCT). Nine (27.3%) had uncontrolled primary disease,
and 4 (12.1%) were on calcineurin inhibitors at the time
of COVID-19 diagnosis. Twelve (85.7%) of allo-HSCT
recipients were transplanted from 10/10 human leukocyte
antigen (HLA) matched related donors, two of them
(14.3%) from haploidentical donors. The patients baseline
characteristics are outlined in Table 1.
Among the patients, 23 (69.7%) of them developed fever
in the course of COVID-19. Twenty (60.6%), 9 (27.3%),
and 4 (12.1%) of the patients had mild, moderate and
severe COVID-19 or critical illness, respectively. Fifteen
(45.5%) were hospitalized, 4 (12.1%) required intensive
care, and 3 patients (9.1%) needed invasive mechanical
ventilation. A patient, who refused hospitalization died at
home. Favipiravir, which is a ribonucleic acid polymerase
inhibitor, was the most common antiviral medication
used by the patients. Detailed COVID-19 outcomes of the
patients are given in Table 2.
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Table 1. Baseline characteristics of the patients*.
Median Age (min-max)

57 (27-71) years

Gender, n (%)
Male

21 (63.6%)

Female
12 (36.4%)
Time from HSCT to COVID-19
868 (31-2368) days
Median (min-max)
Primary Disease (Requiring HSCT), n (%)
MM

9 (27.3%)

HL

1 (3.0%)

NHL

8 (24.2%)

AML

5 (15.2%)

ALL

3 (9.1%)

PID

2 (6.1%)

MF

1 (3.0%)

MDS

3 (9.1%)

ITP

1 (3.0%)

HSCT, n (%)
AHSCT

19 (57.6%)

Allo-HSCT

14 (42.4%)

Uncontrolled Primary Disease, n (%)
9 (27.3%)
Use of Immunosuppressive Drugs, n (%)
4 (12.1%)
(Calcineurin inhibitors)
Donor (n=14)
Full matched donor, n (%)

12 (83.3%)

Haploidentical, n (%)

2 (16.7%)

GVHD, n (%)

6 (18.2%)

Chronic Diseases, n (%)
CAD

4 (12.1 %)

CKD

7 (21.2%)

HT

8 (24.2 %)

COPD

1 (3.0 %)

DM

3 (9.1 %)

Non-hematologic malignancy

2 (6.1 %)

*MM: multiple myeloma, HL: hodgkin-lymphoma: NHL:
nonhodgkin lymphoma, AML: acute myeloid leukemia, ALL:
acute lymphoblastic leukemia, PID: primary immunodeficiency,
MF: mycosis fungoides, MDS: myelodysplastic syndrome, ITP:
immune thrombocytopenia, GVHD: graft versus host disease,
CAD: coronary artery disease, CKD: chronic kidney disease, HT:
hypertension, COPD: chronic obstructive pulmonary disease,
DM: diabetes mellitus.

A total of 6 patients had concomitant graft versus host
disease (GVHD) (acute gastrointestinal and cutaneous:
two patients, chronic cutaneous and gastrointestinal: two
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patients, chronic cutaneous: two patients) at the time of
COVID-19 diagnosis. The course of the GVHD did not get
worse in these patients.
Among the hospitalized patients, 13 (86.7%) of them
were male, and the remaining 2 (13.3%) were female. The
difference was statistically significant (p < 0.05). Hospital
admission rates according to sex, HSCT type, remission
status, and presence of GVHD are given in Table 3.
Median follow-up time was 28 days (2–262 days).
During this time, 3 of 33 patients (9.1%) died. The case
fatality rate was 9.1% in all HSCT recipients, 22.2% in
patients with active hematologic malignancy, 4.2% in
patients without active hematologic malignancy, and
25.0% in who was on immunosuppressive drugs. The
mortality rates according to sex, HSCT type, remission
status, presence of GVHD, and use of immunosuppressive
drugs are given in Table 4.
The mortality and hospitalization rates were calculated
separately for the treatments. The detailed data on

COVID-19 treatments received by the patients are given
in Table 5. The treatment records of a patient who refused
hospitalization and treated at home were not available.
In univariate survival analysis, there was not statistically
significant difference between the AHSCT and allo-HSCT
recipients (p = 0.39). Kaplan–Meier survival curve of
AHSCT and allo-HSCT recipients is shown in Figure.
4. Discussion
Information on the course of COVID-19 in HSCT
recipients remained scarce, and mostly derived from case
series involving limited number of patients. Survival rate
of the HSCT recipients is a matter of debate. Sultan et al.
and Haroon et al. did not report any mortality among 7
and 11 HSCT recipients, respectively [3,5]. However,
Varma et al. published the outcomes of HSCT recipients
with COVID-19 where 32% of the patients were treated in
the intensive care unit and 21% died [7]. In another case
series, 2 of 7 HSCT recipients died due to COVID-19 [8].

Table 2. The clinical findings in HSCT patients.
Symptoms
Fever

23 (69.7%)

Cough

14 (42.4%)

Myalgia

18 (54.6%)

Headache

19 (57.6%)

Anosmia

14 (42.4%)

Diarrhea

5 (15.2%)

Sore throat

4 (12.1%)

Shortness of Breath

10 (30.3%)

COVID-19 Severity
Mild

20 (60.6 %)

Moderate

9 (27.3 %)

Severe or Critical Disease

4 (12.1 %)

Hospitalization
n (%)

15 (45.5%)

Days, median (min-max)

12 (1-57) days

Treatment for COVID-19 (n, %)
Hydroxychloroquine + Favipiravir

5 (15.6%)

Favipiravir

24 (75%)

Azithromycin + Hydroxychloroquine

3 (9.4%)

Intensive Care Unit Admission
n (%)

4 (12.1%)

Days (mean ± SD)

15.2 ± 12.7

Mechanical Ventilation, n (%)

3 (9.1%)

Case Fatality Rate

3/33 (9.1%)

Duration to Death from COVID-19 (days) (mean ± SD)

14.6 ± 6.8
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Table 3. Hospitalization rates according to parameters.
Patients

Hospitalized

Non-Hospitalized

Female (n = 12)

2 (13.3%)

10 (55.6 %)

Male (n = 21)

13 (86.7%)

8 (44.4 %)

AHSCT

8 (53.3%)

11 (61.1 %)

Allo-HSCT

7 (46.7%)

7 (38.9 %)

Yes

7 (46.7%)

2 (11.1%)

No

8 (53.3%)

16 (88.9%)

Yes (n = 6)

2 (28.6 %)

4 (57.1 %)

No (n = 8)

5 (71.4 %)

3 (42.9 %)

P-value

Gender
0.01

HSCT
0.65

Remission Status of Primary Disease
0.47

GVHD (in Allo-HSCT patients, n = 14)
0.59

Table 4. The mortality rates according to parameters.
Patients
(n = 33)

Death
(n = 3)

Survivor
(n = 30)

Male

3 (100.0%)

18 (60.0%)

Female

0 (0.0%)

12 (40.0%)

AHSCT

1 (33.3%)

18 (60.0%)

Allo-HSCT

2 (66.7%)

12 (40.0%)

Yes (n = 9)

2 (66.7%)

7 (23.3%)

No (n = 24)

1 (33.3%)

23 (76.7%)

Yes (n = 4)

1 (33.3%)

3 (10.0%)

No (n = 29)

2 (66.7%)

27 (90.0%)

Yes (n = 6)

1 (50.0%)

5 (41.7%)

No (n = 8)

1 (50.0%)

7 (58.3%)

P- value

Gender
0.2

HSCT
0.56

Remission of Primary Disease
0.174

Use of Immunosuppressive Drug
0.33

GVHD (n=14)

In another study conducted in Spain, mortality was 20% in
allo-HSCT recipients, and 24% in AHSCT recipients [9].
In another study, the CFR was 15.6% in HSCT
recipients. The CFR of the HSCT recipients who were
receiving immunosuppressive treatment was reported as
33% in that study [10]. The patients on immunosuppressive
treatment can be considered at high risk for COVID-19 as
well as other viral infections. In a cohort study examining
the results of 318 HSCT recipients, overall survival 30 days
after the COVID-19 diagnosis was 68% (95% CI 58–77)
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in allo-HSCT recipients and 67% (95% CI 55–78) in
AHSCT recipients [11]. In the present study, case fatality
rate (CFR) is 9.1% (3/33) in all HSCT recipients, 22.2%
(2/9) in patients with active hematologic malignancy,
and 4.2% (1/24) in patients without active hematologic
malignancy. All of the patients received favipiravir as soon
as the diagnosis was made which could lead to favorable
outcome in the present study [12,13]. This study reflects
our experience though with a limited number of HSCT
recipients, given insight in the outcome of HSCT patients
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Table 5. Death and hospitalization rates according to COVID-19 treatment*.
Hydroxychloroquine
+ Favipiravir
n=5

Azithromycin +
Hydroxychloroquine
n=3

Favipiravir
n = 24

Hospitalization

4 (80.0%)

1 (33.3%)

13 (54.2%)

Non-Hospitalized

1 (20.0%)

2 (66.7%)

11 (45.8%)

Dead

0 (0.0%)

0 (0.0%)

3 (12.5%)

Survivor

5 (100.0%)

3 (100.0%)

21 (87.5%)

*For this table n = 32, since the treatment records of a patient were not available.

1.0

Overall Survival

0.8
0.6
AHSCT
Allo-HSCT
AHSCT-censored
Allo-HSCT-censored

0.4
0.2
0.0
0

50
100
150
200
250
Duration after COVID-19 Diagnosis (days)

300

Figure. Overall survival after COVID-19 diagnosis.

with COVID-19 infection. CFR was 9.1% in all patients,
and 4.2% in patients with primary disease in remission.
Based on the data above presented, it can be concluded that
mortality of HSCT recipients is lower in patients whose
primary disease is in remission compared to ones that are
not in remission. Further studies with large group patients
are needed in order to delineate the effects of COVID-19
in HSCT patients.
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